Artículos por temáticas

Mitochondrial dysfunction in Alzheimer's disease: Guiding the path to targeted therapies

McGill Percy KC, Liu Z, Qi X.

Neurotherapeutics. 2025 Apr;22(3):e00525. doi: 10.1016/j.neurot.2025.e00525. Epub 2025 Jan 17.

Diverse role of S100 calcium-binding protein B in alzheimer's disease: pathological mechanisms and therapeutic implications

Sarkar S, Porel P, Kosey S, Aran KR.

Inflammopharmacology. 2025 Apr;33(4):1803-1816. doi: 10.1007/s10787-025-01697-y. Epub 2025 Mar 9.

TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease

Salloway S, Pain A, Lee E, Papka M, Ferguson MB, Wang H, Hu H, Lu M, Oru E, Ardayfio PA, Hoban DB, Collins EC, Brooks DA, Sims JR.

Alzheimers Dement. 2025 May;21(5):e70293. doi: 10.1002/alz.70293.

Involvement of the VGF/BDNF axis in the neuropathology of Alzheimer's disease and its potential role in diagnosis and treatment

Colín-Martínez E, Arias C.

Rev Neurosci. 2024 Nov 19;36(3):267-278. doi: 10.1515/revneuro-2024-0110. Print 2025 Apr 28.

Current amyloid inhibitors: Therapeutic applications and nanomaterial-based innovations

López-García P, Tejero-Ojeda MM, Vaquero ME, Carrión-Vázquez M.

Prog Neurobiol. 2025 Apr;247:102734. doi: 10.1016/j.pneurobio.2025.102734. Epub 2025 Feb 28.

Natural Killer Cells in Alzheimer's Disease: From Foe to Friend

Kostic M, Zivkovic N, Cvetanovic A, Basic J, Stojanovic I.

Eur J Neurosci. 2025 Apr;61(7):e70096. doi: 10.1111/ejn.70096.

Stilbenes Against Alzheimer's Disease: A Comprehensive Review of Preclinical Studies of Natural and Synthetic Compounds Combined with the Contributions of Developed Nanodrug Delivery Systems

Küpeli Akkol E, Karatoprak GŞ, Dumlupınar B, Bahadır Acıkara Ö, Arıcı R, Yücel Ç, Aynal LC, Sobarzo Sánchez E.

Molecules. 2025 Apr 29;30(9):1982. doi: 10.3390/molecules30091982.

Beyond amyloid plaque, targeting α-synuclein in Alzheimer disease: The battle continues

Al-Kuraishy HM, Sulaiman GM, Mohammed HA, Al-Gareeb AI, Albuhadily AK, Ali AA, Abu-Alghayth MH.

Ageing Res Rev. 2025 Mar;105:102684. doi: 10.1016/j.arr.2025.102684. Epub 2025 Feb 4.

Let-7 Family as a Mediator of Exercise on Alzheimer's Disease

Ke S, Liu Z, Wan Y.

Cell Mol Neurobiol. 2025 May 19;45(1):43. doi: 10.1007/s10571-025-01559-9.

Recent Studies on Heterocyclic Cholinesterase Inhibitors Against Alzheimer's Disease

Tok F.

Chem Biodivers. 2025 Apr;22(4):e202402837. doi: 10.1002/cbdv.202402837. Epub 2024 Dec 3.

Bridging gap in the treatment of Alzheimer's disease via postbiotics: Current practices and future prospects

Bashir B, Gulati M, Vishwas S, Gupta G, Dhanasekaran M, Paudel KR, Chellappan DK, Anand K, Negi P, Singh PK, Rajput A, Dua K, Singh SK.

Ageing Res Rev. 2025 Mar;105:102689. doi: 10.1016/j.arr.2025.102689. Epub 2025 Feb 12.

Phytomolecules as Alzheimer's therapeutics: A comprehensive review

Hussain MK, Ahmad M, Khatoon S, Khan MV, Azmi S, Arshad M, Ahamad S, Saquib M.

Eur J Med Chem. 2025 Apr 15;288:117401. doi: 10.1016/j.ejmech.2025.117401. Epub 2025 Feb 17.

Progress in the study of anti-Alzheimer's disease activity of pyrimidine-containing bioactive molecules

Liu YL, Zhang Q, Li BQ, Zhang D, Chui RH, Zhang LL, Zhang Q, Ma LY.

Eur J Med Chem. 2025 Mar 5;285:117199. doi: 10.1016/j.ejmech.2024.117199. Epub 2025 Jan 1.

Understanding of Alzheimer's disease pathophysiology for therapeutic implications of natural products as neuroprotective agents

Prabha S, Choudhury A, Islam A, Thakur SC, Hassan MI.

Ageing Res Rev. 2025 Mar;105:102680. doi: 10.1016/j.arr.2025.102680. Epub 2025 Feb 6.

Advancements in autophagy perturbations in Alzheimer's disease: Molecular aspects and therapeutics

Dhapola R, Kumari S, Sharma P, Vellingiri B, HariKrishnaReddy D.

Brain Res. 2025 Mar 15;1851:149494. doi: 10.1016/j.brainres.2025.149494. Epub 2025 Feb 6.